[ccpw id="5"]

Home.forex news reportWaters forecasts first-quarter profit below Wall Street estimates, shares slide

Waters forecasts first-quarter profit below Wall Street estimates, shares slide

-


Feb 9 (Reuters) – Waters said on Monday it expects first-quarter profit to fall below Wall Street estimates, sending shares of the ​lab equipment maker down nearly 12% in premarket trading as ‌investors weighed the outlook and a revenue decline at the Becton Dickinson unit it acquired ‌last year.

The company, however, forecast better-than-expected full-year profit, reflecting contributions from its $17.5 billion buyout of Becton Dickinson’s bioscience and diagnostics business, which it bought to broaden its reach in clinical and diagnostic applications.

Separately, Becton posted an 8.3% year-over-year ⁠decline in revenue from its ‌life sciences segment, which includes biosciences and diagnostic solutions, for the quarter ended December 31. The business posted sales ‍of $766 million.

“Overall, it looks like the BD revenue came in lighter than expected, so it may be a heavier lift to improve operations in that business… than ​previously expected,” Morningstar analyst Julie Utterback said.

Waters forecast first-quarter profit of $2.25 ‌to $2.35 per share, versus analysts’ average estimate of $2.51, according to LSEG data.

For 2026, Waters said it expects 5.3% combined company sales growth at the midpoint, including the benefit from the acquisition.

It projected 2026 adjusted profit of $14.30 to $14.50 per share, above analysts’ average estimate of $14.32.

Waters expects full-year organic revenue of $3.35 ⁠billion to $3.40 billion, compared with estimates of $3.36 ​billion, and said the acquired Becton Dickinson ​business should add about $3 billion to reported 2026 revenue.

The unit brought in sales of $766 million in the quarter, below analysts’ estimate ‍of $1.3 billion.

Waters supplies ⁠lab equipment and technology globally, with most revenue coming from biopharma customers that use its tools for research and drug development.

The company ⁠reported fourth-quarter adjusted profit of $4.53 per share, topping estimates of $4.51, while revenue rose about 7% ‌to $932 million, compared with expectations of $928.1 million.

(Reporting by Gnaneshwar Rajan ‌in Bengaluru; Editing by Tasim Zahid)



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

LATEST POSTS

How Carriers and Insurers Are Subsidizing Failure

Three hundred bucks, some paperwork, and you’re officially a motor carrier. But insurance, that was supposed to be different. That was...

UBS Lowers Veralto (VLTO) PT to $102 with Neutral Rating

Veralto Corporation (NYSE:VLTO) is one of the best IPO stocks to buy right now. On February 6, UBS analyst Joshua Spector...

Is SharkNinja (SN) One of the Best IPO Stocks to Buy Right Now?

SharkNinja Inc. (NYSE:SN) is one of the best IPO stocks to buy right now. On January 16, JPMorgan raised its price...

Bernstein Initiates Coupang (CPNG) Coverage with Underperform Rating, $17 PT

Coupang Inc. (NYSE:CPNG) is one of the best IPO stocks to buy right now. On February 5, Bernstein initiated coverage of...

Follow us

0FansLike
0FollowersFollow
0SubscribersSubscribe

Most Popular

spot_img